Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mantle cell lymphoma.

Francesco Bertoni1, Emanuele Zucca, Franco Cavalli

  • 1Oncology Institute of Southern Switzerland, Bellinzona, Switzerland. fbertoni@mac.com

Current Opinion in Hematology
|November 19, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Phase Ib Trial of Copanlisib in Combination with Venetoclax in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma-SAKK 66/18 Trial.

Cancers·2026
Same author

IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.

Blood·2026
Same author

Improving the predictive value of end-of-treatment PET/ CT in diffuse large B-cell lymphoma.

Haematologica·2026
Same author

Predicting 2-year time to progression in diffuse large B cell lymphoma using 3D CNNs on whole-body PET/CT scans.

EJNMMI research·2025
Same author

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.

Blood·2025
Same author

IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.

bioRxiv : the preprint server for biology·2025
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Mantle cell lymphoma has a poor prognosis with no current cure. Research is advancing understanding of its biology and genetic targets, but new treatments are urgently needed.

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma with a poor prognosis.
  • Current standard treatments for MCL have not achieved a cure.
  • Further understanding of MCL biology is crucial for developing effective therapies.

Purpose of the Study:

  • To review recent advancements in the understanding of mantle cell lymphoma biology.
  • To summarize current and emerging treatment strategies for mantle cell lymphoma.

Main Methods:

  • Review of recent genomic and expression data in MCL.
  • Analysis of pathological and immunohistochemical findings.
  • Evaluation of current and investigational therapeutic approaches.

Related Experiment Videos

Main Results:

  • Pathology and immunohistochemistry can identify high-risk MCL patient subsets.
  • Antigen selection and specific Ig gene rearrangements correlate with prognosis.
  • Key genetic abnormalities target cell cycle, ATM, and NF-kappaB pathways.
  • Despite progress, therapeutic outcomes remain unsatisfactory.
  • Autologous and allogeneic bone marrow transplantation offer potential for improved outcomes.

Conclusions:

  • Recent research has deepened the understanding of MCL biology and genetic underpinnings.
  • Novel treatment modalities for mantle cell lymphoma are under investigation.
  • Effective curative strategies for mantle cell lymphoma are still lacking.